H-CYTE, Inc. (HCYT)

OTCMKTS: HCYT · Delayed Price · USD
2.21
0.00 (0.00%)
Mar 21, 2023, 12:00 AM EDT - Market closed
Market Cap 1.06M
Revenue (ttm) 778,137
Net Income (ttm) -9.55M
Shares Out 477.61K
EPS (ttm) -40.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100
Open 2.21
Previous Close 2.21
Day's Range 2.21 - 2.21
52-Week Range 2.02 - 68.80
Beta 0.79
Analysts Sell
Price Target n/a
Earnings Date Feb 23, 2023

About HCYT

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Michael W. Yurkowsky
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol HCYT
Full Company Profile

Financial Performance

In 2021, H-CYTE's revenue was $1.61 million, a decrease of -25.07% compared to the previous year's $2.15 million. Losses were -$4.80 million, -25.70% less than in 2020.

Financial Statements

News

H-CYTE Completes Acquisition of SkinDisc™ Regenerative Tissue Kit from Scion Solutions, LLC

Wound Healing and Limb Salvage Technology Added to Growing Asset Portfolio Company's Second Completed Transaction in Four Months

3 months ago - GlobeNewsWire

H-CYTE Announces Intent to Acquire SkinDisc, Expects to Complete Within 30 Days

Wound Healing and Limb Salvaging Technology Adds to Company's Asset Portfolio Focused on Unmet Medical Needs Wound Healing and Limb Salvaging Technology Adds to Company's Asset Portfolio Focused on Un...

6 months ago - GlobeNewsWire

H-CYTE Completes Acquisition of Jantibody

Milestone Achieved as Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer Added to Asset Portfolio Milestone Achieved as Immunotherapeutic Agent Under Investigation for the...

7 months ago - GlobeNewsWire

H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days

Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset Portfolio Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Canc...

8 months ago - GlobeNewsWire

H-CYTE Announces 1-for-1,000 Reverse Stock Split

Strategic Decision to Support Improved Investor Profile and Potential Future Uplisting of Securities to Major Exchange Strategic Decision to Support Improved Investor Profile and Potential Future Upli...

10 months ago - GlobeNewsWire

H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise

Proceeds to Support Inorganic Growth and General Working Capital Purposes Proceeds to Support Inorganic Growth and General Working Capital Purposes

1 year ago - GlobeNewsWire

H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.

Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology Targets one of Healthcare's Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology

1 year ago - GlobeNewsWire